Summit Trail Advisors’s 10x Genomics TXG Stock Holding History

Summit Trail Advisors’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.64M	Sell	225,390 -44,378	-16%	-$1.16M	0.11%	109
2026 Q1	$5.73M	Buy	269,768 +49,382	+22%	+$987K	0.08%	141
2025 Q4	$3.59M	Sell	220,386 -4,259	-2%	-$64.3K	0.06%	185
2025 Q3	$2.63M	Buy	224,645 +83,721	+59%	+$1.09M	0.04%	310
2025 Q2	$1.63M	Buy	140,924 +104,885	+291%	+$956K	0.03%	317
2025 Q1	$315K	Buy	36,039 +25,775	+251%	+$325K	0.01%	320
2024 Q4	$147K	Buy	10,264 +178	+2%	+$2.81K	0.01%	367
2024 Q3	$228K	Buy	+10,086	New	+$209K	0.01%	639

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Summit Trail Advisors's TXG Position: Q2 2026 in Review

Summit Trail Advisors reduced its 10x Genomics (TXG) stake by 16% in Q2 2026, selling an estimated $1.16M and leaving 225,390 shares worth $8.64M. The position accounts for 0.11% of the portfolio, ranked #109.

Summit Trail Advisors first reported a position in TXG in Q3 2024 and has held it in 8 quarters since. 392 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

Summit Trail Advisors held 225,390 shares of 10x Genomics worth $8.64M as of Q2 2026.
Summit Trail Advisors sold 44,378 10x Genomics shares in Q2 2026, an estimated $1.16M.
10x Genomics made up 0.11% of Summit Trail Advisors's portfolio in Q2 2026, its #109 holding.
Summit Trail Advisors first reported a position in 10x Genomics in Q3 2024 and has held it in 8 quarters since.
392 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Summit Trail Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.